RU2756743C2 - Замещенные гетероарилом пиридины и способы применения - Google Patents

Замещенные гетероарилом пиридины и способы применения Download PDF

Info

Publication number
RU2756743C2
RU2756743C2 RU2018138707A RU2018138707A RU2756743C2 RU 2756743 C2 RU2756743 C2 RU 2756743C2 RU 2018138707 A RU2018138707 A RU 2018138707A RU 2018138707 A RU2018138707 A RU 2018138707A RU 2756743 C2 RU2756743 C2 RU 2756743C2
Authority
RU
Russia
Prior art keywords
independently selected
formula
optionally substituted
sulfonyl
amino
Prior art date
Application number
RU2018138707A
Other languages
English (en)
Russian (ru)
Other versions
RU2018138707A (ru
RU2018138707A3 (OSRAM
Inventor
Роберт Дж. АЛЬТЕНБАХ
Эндрю БОГДАН
Дьюванни Петру Диунизу КОТИ
Марлон Д. КАУЭРТ
Стефен Н ГРЕСЛЕР
Ханс КЕЛГТЕРМАНС
Филип Р. КИМ
ДЕР ПЛАС Стивен Эмиль ВАН
Сюэцин ВАН
Original Assignee
Эббви Глобал Энтерпрайзис Лтд.
Галапагос Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Глобал Энтерпрайзис Лтд., Галапагос Нв filed Critical Эббви Глобал Энтерпрайзис Лтд.
Publication of RU2018138707A publication Critical patent/RU2018138707A/ru
Publication of RU2018138707A3 publication Critical patent/RU2018138707A3/ru
Application granted granted Critical
Publication of RU2756743C2 publication Critical patent/RU2756743C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018138707A 2016-06-03 2017-05-24 Замещенные гетероарилом пиридины и способы применения RU2756743C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345315P 2016-06-03 2016-06-03
US62/345,315 2016-06-03
PCT/IB2017/053068 WO2017208115A1 (en) 2016-06-03 2017-05-24 Heteroaryl substituted pyridines and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021127810A Division RU2021127810A (ru) 2016-06-03 2017-05-24 Замещенные гетероарилом пиридины и способы применения

Publications (3)

Publication Number Publication Date
RU2018138707A RU2018138707A (ru) 2020-07-14
RU2018138707A3 RU2018138707A3 (OSRAM) 2020-08-24
RU2756743C2 true RU2756743C2 (ru) 2021-10-05

Family

ID=59014678

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018138707A RU2756743C2 (ru) 2016-06-03 2017-05-24 Замещенные гетероарилом пиридины и способы применения
RU2021127810A RU2021127810A (ru) 2016-06-03 2017-05-24 Замещенные гетероарилом пиридины и способы применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021127810A RU2021127810A (ru) 2016-06-03 2017-05-24 Замещенные гетероарилом пиридины и способы применения

Country Status (35)

Country Link
US (2) US10138227B2 (OSRAM)
EP (1) EP3464282B1 (OSRAM)
JP (3) JP6968094B2 (OSRAM)
KR (2) KR102719916B1 (OSRAM)
CN (2) CN109311864B (OSRAM)
AR (2) AR108672A1 (OSRAM)
AU (3) AU2017273215B2 (OSRAM)
CA (1) CA3022216A1 (OSRAM)
CL (1) CL2018003323A1 (OSRAM)
CO (1) CO2018012171A2 (OSRAM)
CR (1) CR20180547A (OSRAM)
CY (1) CY1124031T1 (OSRAM)
DK (1) DK3464282T3 (OSRAM)
DO (1) DOP2018000257A (OSRAM)
EC (1) ECSP18094790A (OSRAM)
ES (1) ES2806873T3 (OSRAM)
HR (1) HRP20201068T1 (OSRAM)
HU (1) HUE050248T2 (OSRAM)
IL (3) IL303196B2 (OSRAM)
LT (1) LT3464282T (OSRAM)
MX (2) MX385054B (OSRAM)
MY (1) MY199604A (OSRAM)
PE (1) PE20190511A1 (OSRAM)
PH (1) PH12018502534B1 (OSRAM)
PL (1) PL3464282T3 (OSRAM)
PT (1) PT3464282T (OSRAM)
RS (1) RS60574B1 (OSRAM)
RU (2) RU2756743C2 (OSRAM)
SG (1) SG11201808842VA (OSRAM)
SI (1) SI3464282T1 (OSRAM)
SM (1) SMT202000394T1 (OSRAM)
TW (4) TW202515560A (OSRAM)
UY (2) UY37272A (OSRAM)
WO (1) WO2017208115A1 (OSRAM)
ZA (1) ZA201808423B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100921397B1 (ko) * 2009-02-09 2009-10-14 (주)오엠티 인쇄회로기판의 세척장비 및 이를 이용한 세척방법
DK3203840T3 (da) 2014-10-06 2020-08-31 Vertex Pharma Modulatorer af cystisk fibrose-transmembrankonduktansregulator
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MD3551622T2 (ro) 2016-12-09 2021-03-31 Vertex Pharma Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
WO2018227049A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
ES2912657T3 (es) 2017-08-02 2022-05-26 Vertex Pharma Procesos para preparar compuestos de pirrolidina
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
MA50400A (fr) 2017-10-19 2020-08-26 Vertex Pharma Formes cristallines et compositions de modulateurs de cftr
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
CA3088577A1 (en) 2018-02-15 2019-08-22 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
IT201900000687A1 (it) * 2019-01-16 2020-07-16 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US11236067B2 (en) 2019-07-12 2022-02-01 Orphomed, Inc. Compound for treating cystic fibrosis
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
CA3150162A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
BR112022009185A2 (pt) * 2019-11-12 2022-07-26 Genzyme Corp Heteroarilaminossulfonamidas de 5 membros para tratar afecções mediadas por atividade de cftr deficiente
AU2021329507A1 (en) 2020-08-20 2023-03-09 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating respiratory diseases characterized by mucus hypersecretion
CA3204725A1 (en) 2020-12-10 2022-06-16 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US20220211692A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
CA3223599A1 (en) 2021-08-19 2023-02-23 Peter FINKBEINER Method for controlling diamide resistant pests & compounds therefor
JP2025530377A (ja) 2022-09-15 2025-09-11 イドルシア・ファーマシューティカルズ・リミテッド 大環状ｃｆｔｒ調節剤とｃｆｔｒコレクター及び／又はｃｆｔｒポテンシエーターとの合剤
EP4587443A1 (en) 2022-09-15 2025-07-23 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法
WO2025186214A1 (en) 2024-03-05 2025-09-12 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011074B1 (ru) * 2004-03-30 2008-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Гидразидсодержащие соединения - ингибиторы cftr и их применение
WO2009076593A1 (en) * 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2013038386A1 (en) * 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2016193812A1 (en) * 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2810655C (en) 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8283351B2 (en) * 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
HUE025553T2 (en) 2007-05-25 2016-02-29 Vertex Pharma CFTR modulators
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
WO2010048573A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
NZ592685A (en) * 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
US8367660B2 (en) 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2011008931A2 (en) * 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders
US8247436B2 (en) * 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
BR112013007907A2 (pt) 2010-10-08 2016-06-14 N30 Pharmaceuticals Inc novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase
WO2012154880A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
DK2760463T3 (en) 2011-09-20 2019-03-18 Univ North Carolina Chapel Hill REGULATION OF SODIUM CHANNELS USING PLUNC PROTEINS
CN105531268B (zh) 2013-05-07 2017-09-12 加拉佩格斯股份有限公司 用于治疗囊性纤维化的新化合物及其药物组合物
EP3030568B1 (en) 2013-08-08 2018-09-19 Galapagos NV Thieno[2,3-c]pyrans as cftr modulators
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3116501A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
JP6676646B2 (ja) 2014-10-31 2020-04-08 アッヴィ・エス・ア・エール・エル 置換クロマンおよび使用方法
CN107427490A (zh) 2014-10-31 2017-12-01 艾伯维公司 取代的四氢吡喃和使用方法
EP3277647A1 (en) * 2015-03-31 2018-02-07 Vertex Pharmaceuticals (Europe) Limited Deuterated vx-661
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
US9890158B2 (en) 2015-10-09 2018-02-13 Abbvie S.Á.R.L. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US9796711B2 (en) 2015-10-09 2017-10-24 Abbvie S.Á.R.L. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and method of use
JP2019514840A (ja) 2016-04-26 2019-06-06 アッヴィ・エス・ア・エール・エル 嚢胞性線維症膜コンダクタンス制御因子タンパク質のモジュレータ
US10138227B2 (en) * 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011074B1 (ru) * 2004-03-30 2008-12-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Гидразидсодержащие соединения - ингибиторы cftr и их применение
WO2009076593A1 (en) * 2007-12-13 2009-06-18 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2013038386A1 (en) * 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2016193812A1 (en) * 2015-06-02 2016-12-08 Abbvie S.A.R.L. Substituted pyridines and method of use

Also Published As

Publication number Publication date
TW202214614A (zh) 2022-04-16
KR20220162806A (ko) 2022-12-08
CN109311864B (zh) 2022-05-10
CL2018003323A1 (es) 2019-03-22
NZ788542A (en) 2025-06-27
JP7622122B2 (ja) 2025-01-27
KR102719916B1 (ko) 2024-10-23
AR124916A2 (es) 2023-05-17
EP3464282A1 (en) 2019-04-10
SMT202000394T1 (it) 2020-09-10
JP2023172889A (ja) 2023-12-06
ZA201808423B (en) 2019-08-28
RS60574B1 (sr) 2020-08-31
KR102469995B1 (ko) 2022-11-24
RU2018138707A (ru) 2020-07-14
IL262415A (en) 2018-12-31
AU2017273215A1 (en) 2018-10-25
SG11201808842VA (en) 2018-11-29
DK3464282T3 (da) 2020-07-27
AR108672A1 (es) 2018-09-12
AU2024202468A1 (en) 2024-05-02
TW201802085A (zh) 2018-01-16
US10604515B2 (en) 2020-03-31
IL262415B (en) 2021-12-01
RU2021127810A (ru) 2021-10-25
IL288243A (en) 2022-01-01
US10138227B2 (en) 2018-11-27
CA3022216A1 (en) 2017-12-07
RU2018138707A3 (OSRAM) 2020-08-24
JP2022009448A (ja) 2022-01-14
IL288243B1 (en) 2023-07-01
JP7392211B2 (ja) 2023-12-06
PH12018502534B1 (en) 2020-09-23
ES2806873T3 (es) 2021-02-18
ECSP18094790A (es) 2019-01-31
TW202329959A (zh) 2023-08-01
IL303196B2 (en) 2025-04-01
CN114671864B (zh) 2025-04-08
TWI752961B (zh) 2022-01-21
CO2018012171A2 (es) 2018-11-30
BR112018074815A2 (pt) 2019-03-19
SI3464282T1 (sl) 2020-12-31
WO2017208115A1 (en) 2017-12-07
KR20190015215A (ko) 2019-02-13
IL303196B1 (en) 2024-12-01
PL3464282T3 (pl) 2020-12-14
DOP2018000257A (es) 2018-12-31
US20170349576A1 (en) 2017-12-07
LT3464282T (lt) 2020-09-10
NZ747222A (en) 2025-06-27
TW202515560A (zh) 2025-04-16
PH12018502534A1 (en) 2019-10-21
UY37272A (es) 2018-01-02
IL303196A (en) 2023-07-01
TWI849782B (zh) 2024-07-21
UY40612A (es) 2024-02-15
MX2021009322A (es) 2021-09-08
HRP20201068T1 (hr) 2020-11-13
JP2019517455A (ja) 2019-06-24
CN109311864A (zh) 2019-02-05
AU2021282409B2 (en) 2024-01-18
US20190055229A1 (en) 2019-02-21
MY199604A (en) 2023-11-08
AU2017273215B2 (en) 2021-09-09
IL288243B2 (en) 2023-11-01
PE20190511A1 (es) 2019-04-10
TWI797926B (zh) 2023-04-01
CR20180547A (es) 2019-10-30
AU2021282409A1 (en) 2021-12-23
EP3464282B1 (en) 2020-04-22
CN114671864A (zh) 2022-06-28
JP6968094B2 (ja) 2021-11-17
MX385054B (es) 2025-03-14
MX2018014758A (es) 2019-04-29
HUE050248T2 (hu) 2020-12-28
CY1124031T1 (el) 2022-03-24
PT3464282T (pt) 2020-07-17

Similar Documents

Publication Publication Date Title
RU2756743C2 (ru) Замещенные гетероарилом пиридины и способы применения
US10047051B2 (en) Substituted pyridines and method of use
HK40006841B (en) Heteroaryl substituted pyridines and methods of use
HK40006841A (en) Heteroaryl substituted pyridines and methods of use
BR122024019066A2 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística
BR112018074815B1 (pt) Composto de piridina substituída com heteroarila
BR122024019066B1 (pt) Composto de piridina substituída com heteroarila, composições farmacêuticas que compreendem o mesmo e usos do mesmo para tratar fibrose cística

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant